IDiyas

For the Inventor, By the Inventor

Berlin, Germany

Karl-Heinrich Fritzemeier

USPTO Granted Patents = 30 

 

Average Co-Inventor Count = 5.8

ph-index = 7

Forward Citations = 235(Granted Patents)


Company Filing History:

goldMedal28 out of 1,384 
 
Schering Aktiengesellschaft
 patents
silverMedal1 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
bronzeMedal1 out of 1 
 
Schering Akitengesellschaft
 patent

Years Active: 1993-2013

Loading Chart...
Loading Chart...
30 patents (USPTO):Explore Patents
1. 8445469 - 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter (2013-05-21),
2. 7414043 - 9-α-substituted estratrienes as selectively active estrogens (2008-08-19),
3. 7378404 - 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens (2008-05-27),
4. 7119082 - 11β-long-chain-substituted 19-nor-17α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring (2006-10-10),
5. 7109360 - 16-hydroxyestratrienes as selectively active estrogens (2006-09-19),
6. 7074829 - Antiestrogens, process for their production and their pharmaceutical use (2006-07-11),
7. 6958327 - 18 Norsteroids as selectively active estrogens (2005-10-25),
8. 6844336 - 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity (2005-01-18),
9. 6794409 - Use of ER&bgr;-selective ligands for regulating fertility and compounds useful therefor (2004-09-21),
10. 6790843 - C-19-halogen-substituted steroids of the androst-9(11)-ene-series, methods for the production and use thereof (2004-09-14),
11. 6790842 - 11&bgr; LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11&bgr; LONG-CHAIN SUBSTITUTED ESTATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS (2004-09-14),
12. 6780855 - 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS (2004-08-24),
13. 6670347 - 19-nor-17&agr;-pregna-1,3,5(10)-trien-17&bgr;-ols with a 21,16&agr;-lactone ring (2003-12-30),
14. 6596713 - Steroid esters and amides, process for their production and their pharmaceutical use (2003-07-22),
15. 6559181 - Antiestrogens, process for their protection and their pharmaceutical use (2003-05-06),

Title: The Innovative Contributions of Karl-Heinrich Fritzemeier

Introduction

Karl-Heinrich Fritzemeier, based in Berlin, Germany, is a prolific inventor known for his significant contributions to the field of pharmaceuticals. With approximately 30 patents registered to his name, Fritzemeier has made notable strides in developing innovative compounds that have therapeutic applications in treating various conditions.

Latest Patents

Among Karl-Heinrich Fritzemeier's latest patents are groundbreaking inventions such as 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones and related pharmaceutical preparations. Another remarkable patent involves the creation of 9-α-substituted estratrienes, which are selectively active estrogens. This invention highlights the new compounds that exhibit a higher affinity to estrogen receptor preparations from rat prostates than to those from rat uteri, indicating their potential for targeted therapeutic use. These estratrienes may help treat diseases and conditions induced by estrogen deficiency, showcasing the vital role of Fritzemeier's work in the medical field.

Career Highlights

Fritzemeier's career includes significant positions at renowned companies such as Schering Aktiengesellschaft and Bayer Intellectual Property GmbH. His work in these prestigious organizations has allowed him to influence the direction of pharmaceutical research and development, leading to the creation of innovative treatments.

Collaborations

Throughout his career, Karl-Heinrich Fritzemeier has collaborated with respected colleagues, including Rolf Krattenmacher and Christa Hegele-Hartung. These partnerships have further enhanced the scope and impact of his research, ultimately contributing to the advancement of pharmaceutical sciences.

Conclusion

Karl-Heinrich Fritzemeier’s extensive patent portfolio and innovative research underscore his prominent role in the field of pharmaceuticals. His inventions not only reflect his dedication to advancing medical science but also have the potential to improve patient care by addressing critical health needs. As he continues to develop and refine his ideas, Fritzemeier remains a significant figure in the world of invention and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…